Indications for Fluphenazine Decanoate Inj:
Depot parenteral for psychosis.
Initially: 12.5–25mg IM or SC every 4–6 wks; max 100mg/dose.
Coma. CNS or bone marrow depression. Liver disease. Subcortical brain damage. Blood dyscrasias.
Cardiovascular or renal disease. Pheochromocytoma. Seizures. Glaucoma. History of breast cancer. Exposure to extreme heat or organophosphates. Gradually reduce to lowest effective maintenance dose. Monitor blood, liver, renal, and ocular function. Mental retardation. Surgery. Pregnancy. Nursing mothers.
Potentiates anticholinergics, CNS depression with alcohol and other CNS depressants; both drugs with propranolol. Antagonized by anticholinergics. Decreased guanethidine effects. May cause false (+) pregnancy test.
Drowsiness, anticholinergic and other autonomic effects, insomnia, restlessness, rash, photosensitivity, tardive dyskinesia, blood dyscrasias, jaundice, pneumonia, hypertension, retinopathy, lowered seizure threshold, extrapyramidal reactions, neuroleptic malignant syndrome, weight changes, endocrine effects.
Formerly known under the brand names Prolixin (tabs, concentrate, elixir, inj); Permitil (tabs, concentrate); Prolixin Decanoate (decanoate inj).